CDK4/6 Inhibition Improves Progression-free Survival in Endometrial Cancer |
Clinical News
eMediNexus Coverage from: 
CDK4/6 Inhibition Improves Progression-free Survival in Endometrial Cancer

0 Read Comments                

Women with advanced, hormone receptor (HR)-positive cervical cancer lived over twice as long without disease progression if they were given the CDK inhibitor palbociclib in association with hormonal therapy, suggested a small randomized trial.

Median progression-free survival (PFS) was found to increase from 3.0 months with letrozole alone to 8.3 months with letrozole and palbociclib. The disease control rate (DCR, response plus stable disease) with the combination was 63.6% compared to 37.8% with letrozole alone.Adding letrozole also added toxicity, as one-fourth of patients in the combination group discontinued treatment due to adverse events (AEs), but the regimen was tolerablein most patients, reported Mansoor R. Mirza, MD, of Copenhagen University Hospital, at the 2020 European Society for Medical Oncology (ESMO) virtual congress… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now